56 results
10-K/A
2023 FY
VCNX
Vaccinex Inc
25 Apr 24
Annual report (amended)
3:00pm
Year Ended December 31, | ||||||||
2023 | 2022 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net loss | $ | (20,251) | $ | (19,815) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 119 | 207 | ||||||
Stock-based compensation | 474 | 545 | ||||||
Change in fair value of warrant liability | 2,106 | - | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (786) | (175) | ||||||
Prepaid expenses and other current assets | 59 | (94) | ||||||
Accounts payable | 521 | 457 | ||||||
Accrued expenses | 461 | (199) | ||||||
Deferred revenue | 63 | - | ||||||
Net cash used in operating activities | (17,234) | (19,074) | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Purchase of property and equipment | (67) | (99) | ||||||
Net cash used in investing activities | (67) | (99) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Proceeds from issuance of common stock, and pre-funded warrants | 4,971 | - | ||||||
Proceeds from issuance of common stock | 1,278 | 3,560 | ||||||
Proceeds from private offering of common stock | 6,270 | 13,490 | ||||||
Payments of long-term debt | (74) | (75) | ||||||
Net cash provided by financing activities | 12,445 | 16,975 | ||||||
NET DECREASE IN CASH AND CASH EQUIVALENTS | (4,856) | (2,198) | ||||||
CASH AND CASH EQUIVALENTS–Beginning of period | 6,391 | 8,589 | ||||||
CASH AND CASH EQUIVALENTS–End of period | $ | 1,535 | $ | 6,391 |
10-K/A
2023 FY
VCNX
Vaccinex Inc
25 Apr 24
Annual report (amended)
3:00pm
Common Stock | Treasury Stock | |||||||||||||||||||||||||||
Shares | Amount | Additional Paid-in Capital | Common Stock Shares | Amount | Accumulated Deficit | Total Stockholders’ Equity/(Deficit) | ||||||||||||||||||||||
Balance as of January 1, 2022 | 146,676 | $ | - | $ | 307,284 | 5 | $ | (11) | $ | (299,861) | $ | 7,412 | ||||||||||||||||
Issuance of common stock in private placement offerings | 90,856 | - | 17,051 | - | - | - | 17,051 | |||||||||||||||||||||
Stock-based compensation | - | - | 545 | - | - | - | 545 | |||||||||||||||||||||
Net loss | - | - | - | - | - | (19,815) | (19,815) | |||||||||||||||||||||
Balance as of December 31, 2022 | 237,532 | - | 324,880 | 5 | (11) | (319,676) | 5,193 | |||||||||||||||||||||
Issuance of common stock in private placement offerings | 94,087 | - | 6,024 | - | - | - | 6,024 | |||||||||||||||||||||
Issuance of common stock and pre-funded warrants | 542,857 | - | 4,971 | - | - | - | 4,971 | |||||||||||||||||||||
Issuance of common stock | 18,146 | 1,278 | 1,278 | |||||||||||||||||||||||||
Stock-based compensation | - | - | 474 | - | - | - | 474 | |||||||||||||||||||||
Net loss | - | - | - | - | - | (20,251) | (20,251) | |||||||||||||||||||||
Balance as of December 31, 2023 | 892,622 | $ | - | $ | 337,627 | 5 | $ | (11) | $ | (339,927) | $ | (2,311) | ||||||||||||||||
10-K/A
2023 FY
VCNX
Vaccinex Inc
25 Apr 24
Annual report (amended)
3:00pm
As of December 31, 2023 | As of December 31, 2022 | |||||||
Leasehold improvements | $ | 3,277 | $ | 3,259 | ||||
Research equipment | 3,351 | 3,515 | ||||||
Furniture and fixtures | 350 | 350 | ||||||
Computer equipment | 250 | 321 | ||||||
Property and equipment, gross | 7,228 | 7,445 | ||||||
Less: accumulated depreciation and amortization | (7,091) | (7,256) | ||||||
Property and equipment, net | $ | 136 | $ | 189 |
10-K/A
2023 FY
VCNX
Vaccinex Inc
25 Apr 24
Annual report (amended)
3:00pm
As of December 31, 2023 | ||||||||||||||||
Fair Value | Level 1 | Level 2 | Level 3 | |||||||||||||
Financial Assets: | ||||||||||||||||
Cash equivalents: | ||||||||||||||||
Money market fund | $ | 1,337 | $ | 1,337 | $ | - | $ | - | ||||||||
Total Financial Assets | $ | 1,337 | $ | 1,337 | $ | - | $ | - |
10-K/A
2023 FY
VCNX
Vaccinex Inc
25 Apr 24
Annual report (amended)
3:00pm
Public Warrants | Private Placement Warrants | Total | ||||||||||
Warrant liabilities as of January 1, 2023 | $ | - | $ | - | $ | - | ||||||
Issuance of warrants | 4,325 | 132 | 4,457 | |||||||||
Change in fair value | (2,050) | (56) | (2,106) | |||||||||
Warrant liabilities as of December 31, 2023 | $ | 2,275 | $ | 76 | $ | 2,351 |
10-K/A
jxcgx8 ezcsbo
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
5rnrg5pj86d0 z11y0
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
aadsk79 nt87zyd
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
06pv2 6e0qlemo5evrb
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
bzixza0lg2o
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
mbdc ppx5r2slgr
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
dtpx e0mcd6h
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
dx3gyeug9d5fi
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
lvjj29pmovxp 2rrul
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
y687hv5
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
3tpnxdh3kszr7d 6d
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
ezk1yaevun9f ok8asai
25 Apr 24
Annual report (amended)
3:00pm
10-K/A
jt2zfpsd8tncf sl
25 Apr 24
Annual report (amended)
3:00pm